title: Whole-genome sequencing in personalized therapeutics.
abstract: Eleven years since the initial drafts of the human genome were published, we have begun to see the first examples of the application of whole-genome sequencing to personalized diagnosis and therapeutics. The exponential decline in sequencing costs and the constant improvement in these technologies promise to further advance the use of a patient's full genetic profile in the clinic. However, realizing the potential benefit of such sequencing will require a concerted effort by science, medicine, law, and management. In this review, we discuss current approaches to decoding the 6 billion-letter genetic code of a whole genome in a clinical context, give current examples of translating this information into therapy-guiding knowledge, and list the challenges that will need to be surmounted before these powerful data can be fully exploited to forward the goals of personalized medicine.
authors.affiliation: Program in Biomedical Informatics, Stanford University, Stanford, California, USA.
authors.forename: P
authors.initials: P
authors.lastname: Cordero
authors.forename: E A
authors.initials: EA
authors.lastname: Ashley
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D004247:DNA / Q000235:genetics; D004358:Drug Therapy / Q000639:trends*; D005820:Genetic Testing; D014644:Genetic Variation; D015894:Genome, Human / Q000235:genetics*; D056914:Genomic Structural Variation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D057285:Precision Medicine / Q000639:trends*; D011315:Preventive Medicine; D011544:Pseudogenes / Q000235:genetics; D012091:Repetitive Sequences, Nucleic Acid
chemical_list: D000970:Antineoplastic Agents; D004247:DNA